Apr 22, 2015
Regarding this week’s Teva/Mylan/Perrigo news, early postures point to a drawn out affair, writes Casey McDonald.
Pharmaceutical Executive: Apr 20, 2015
The task of imitating substantially complex molecular entities offers up a host of new operational questions for pharma, writes Casey McDonald.
Apr 19, 2015
Reflector edges through the complex terrain that is health technology assessment in Europe.
Apr 16, 2015
Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.
Apr 15, 2015
Leela Barham looks at what the rival parties are promising for healthcare ahead of the UK General Election next month.
Pharmaceutical Executive: Apr 13, 2015
Casey McDonald asks, is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?
Pharmaceutical Executive: Apr 11, 2015
FDA is under pressure to moderate oversight of pharma advertising and promotion.
Apr 11, 2015
The announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.
Apr 06, 2015
That the UK's NHS has struck a deal for a national roll-out of Bexsero, GSK's vaccine for Meningitis B in infants, is good, but it needs to do better, writes Leela Barham.
Apr 01, 2015
Dr. Anuj Gupta explains the potential implications of the GST— or the goods and services tax — on Indian pharma.